This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
NewCo’s pipeline includes five investigational medicines
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations
Subscribe To Our Newsletter & Stay Updated
